The INTS7 antibody is designed to target the Integrator Complex Subunit 7 (INTS7), a component of the Integrator complex, a multi-protein assembly implicated in RNA polymerase II (RNAPII)-mediated transcription regulation. The Integrator complex, composed of at least 12 subunits (INTS1–12), plays dual roles in RNA processing and transcriptional regulation. Specifically, INTS7 is critical for the structural integrity and enzymatic activity of the complex, facilitating interactions with other subunits and RNAPII. It contributes to the cleavage of nascent RNAs, including small nuclear RNAs (snRNAs) and enhancer RNAs (eRNAs), and modulates transcriptional pausing or termination at specific loci. Dysregulation of INTS7 has been linked to developmental defects and cancers, underscoring its importance in gene expression control. The INTS7 antibody is widely used in molecular biology research to investigate its expression, localization, and function via techniques like Western blotting, immunoprecipitation, and immunofluorescence. It aids in elucidating mechanisms of transcriptional regulation, RNA processing, and disease pathogenesis. Commercial INTS7 antibodies are typically validated for specificity and sensitivity across human, mouse, or rat models, supporting studies in cancer biology, neurodevelopment, and epigenetic research.